Skip to main content

Drug Interactions between abacavir / lamivudine / zidovudine and cabozantinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

lamiVUDine cabozantinib

Applies to: abacavir / lamivudine / zidovudine and cabozantinib

MONITOR: Coadministration of cabozantinib with multidrug resistance-associated proteins (MRP2) inhibitors may increase exposure and toxicity of cabozantinib. In vitro studies have shown MRP2 inhibitors may increase the plasma concentrations of cabozantinib, a MRP2 substrate. The clinical relevance of this finding is not known.

MANAGEMENT: Caution is advised if cabozantinib is used concomitantly with a MRP2 inhibitor. Monitor for cabozantinib toxicity, such as gastrointestinal perforations and fistulas, hemorrhage, thrombotic events, hypertension, diarrhea, and palmar-plantar erythrodysesthesia. Dose reductions, interruption or discontinuation of cabozantinib may be necessary if toxicity occurs.

References (4)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. (2012) "Product Information. Cometriq (cabozantinib)." Exelixis Inc
  4. (2016) "Product Information. Cabometyx (cabozantinib)." Exelixis Inc
Moderate

abacavir cabozantinib

Applies to: abacavir / lamivudine / zidovudine and cabozantinib

MONITOR: Coadministration of cabozantinib with multidrug resistance-associated proteins (MRP2) inhibitors may increase exposure and toxicity of cabozantinib. In vitro studies have shown MRP2 inhibitors may increase the plasma concentrations of cabozantinib, a MRP2 substrate. The clinical relevance of this finding is not known.

MANAGEMENT: Caution is advised if cabozantinib is used concomitantly with a MRP2 inhibitor. Monitor for cabozantinib toxicity, such as gastrointestinal perforations and fistulas, hemorrhage, thrombotic events, hypertension, diarrhea, and palmar-plantar erythrodysesthesia. Dose reductions, interruption or discontinuation of cabozantinib may be necessary if toxicity occurs.

References (4)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. (2012) "Product Information. Cometriq (cabozantinib)." Exelixis Inc
  4. (2016) "Product Information. Cabometyx (cabozantinib)." Exelixis Inc

Drug and food interactions

Moderate

cabozantinib food

Applies to: cabozantinib

ADJUST DOSING INTERVAL: Food may alter the oral bioavailability of cabozantinib. When healthy subjects were given a single 140 mg oral dose with a high-fat meal, cabozantinib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 41% and 57%, respectively, relative to administration under fasting conditions. In clinical studies, patients were administered cabozantinib without food.

GENERALLY AVOID: Coadministration with grapefruit juice is likely to increase the plasma concentrations of cabozantinib, which is primarily metabolized by CYP450 3A4. However, the interaction has not been studied. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.

MANAGEMENT: Cabozantinib should be administered at least one hour before or two hours after a meal. The consumption of grapefruit, grapefruit juice, and supplements that contain grapefruit extract should be avoided.

References (1)
  1. (2012) "Product Information. Cometriq (cabozantinib)." Exelixis Inc
Minor

zidovudine food

Applies to: abacavir / lamivudine / zidovudine

Food may have variable effects on the oral bioavailability of zidovudine. Fatty foods have been reported to decrease the rate and extent of zidovudine absorption following oral administration. In a study of 13 AIDS patients, mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of zidovudine were 2.8 and 1.4 times higher, respectively, in fasting patients than in those administered the medication with breakfast. In addition, variations in plasma zidovudine concentrations were increased when administered in the fed state. In another study of eight patients, the time to reach peak concentration (Tmax) was increased from 0.68 to 1.95 hours, and Cmax was reduced by 50% when zidovudine was administered with a liquid high-fat meal relative to fasting. Protein meals can also delay the absorption and reduce the Cmax of zidovudine, although the extent of absorption is not significantly affected. The clinical significance of these alterations, if any, is unknown. The product labeling states that zidovudine may be taken with or without food.

References (4)
  1. Lotterer E, Ruhnke M, Trautman M, et al. (1991) "Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal." Eur J Clin Pharmacol, 40, p. 305-8
  2. Unadkat JD, Collier AC, Crosby SS, et al. (1990) "Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal." AIDS, 4, p. 229-32
  3. (2001) "Product Information. Retrovir (zidovudine)." Glaxo Wellcome
  4. Sahai J, Gallicano K, Garber G, et al. (1992) "The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients." Br J Clin Pharmacol, 33, p. 657-60

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.